drugset / Trial / NCT02240459

A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment

NCT02240459

Phase 2 Completed 47 enrolled University of Alberta Pfizer · collab
RandomizedCrossoverQuadruple-blindOther

Summary

The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people with overactive bladder and mild cognitive impairment.

Timeline

Start
2016-08
Primary completion
2020-01-31
Completion
2020-01-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Fesoterodine Other / unclassified 4 mg Oral
Subject Fesoterodine Other / unclassified 8 mg Oral
Subject Oxybutynin Small molecule 5 mg